ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,018Medicare Part D Prescriptions Filled, Including Refills

Rank: 663 out of 5176

$602K Total Retail Price of All Prescriptions

Rank: 812 out of 5176

553 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
81% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

12% of this provider’s 553 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

9% of this provider’s 553 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

1% of this provider’s 8,454 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

33% of this provider’s prescriptions were for brand-name drugs, compared to an average of 30%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
SIMVASTATIN 472 427 1 1
FUROSEMIDE 342 312 2 8
OMEPRAZOLE 312 289 3 3
AMLODIPINE BESYLATE 302 268 4 2
METOPROLOL SUCCINATE 280 263 5 11
METFORMIN HCL 250 200 6 7
LOSARTAN POTASSIUM 244 213 7 14
METOPROLOL TARTRATE 244 209 7 6
LISINOPRIL 216 200 9 5
ATORVASTATIN CALCIUM 203 168 10 9
DIOVAN 188 185 11 19
TAMSULOSIN HCL 183 175 12 20
CARVEDILOL 179 161 13 24
CLOPIDOGREL 173 154 14 26
GLIPIZIDE 166 138 15 63
LEVOTHYROXINE SODIUM 165 137 16 4
LACTULOSE 164 148 17 87
PLAVIX 158 142 18 29
MELOXICAM 133 110 19 53
CRESTOR 132 107 20 15
NEXIUM 109 95 21 16
ZOLPIDEM TARTRATE 105 63 22 17
NAMENDA 103 103 23 47
FLUTICASONE PROPIONATE 98 98 24 38
GABAPENTIN 95 61 25 21
ISOSORBIDE MONONITRATE ER 94 94 26 44
PANTOPRAZOLE SODIUM 88 85 27 61
OXYCODONE-ACETAMINOPHEN 87 66 S2 28 101
VENTOLIN HFA 82 45 29 64
GLYBURIDE 81 70 R 30 67
CITALOPRAM HBR 79 65 31 31
JANUVIA 79 76 31 25
DONEPEZIL HCL 79 79 31 28
RAMIPRIL 75 74 34 50
HYDROCHLOROTHIAZIDE 71 57 35 10
TRAMADOL HCL 69 54 36 40
PREDNISONE 68 53 37 52
SINGULAIR 67 45 38 62
ACETAMINOPHEN-CODEINE 63 53 S3 39 127
ADVAIR DISKUS 62 41 40 32
ALLOPURINOL 60 57 41 41
NAPROXEN 59 44 42 95
WARFARIN SODIUM 53 39 43 13
ALENDRONATE SODIUM 53 49 43 18
DIOVAN HCT 52 52 45 39
DILTIAZEM 24HR CD 52 52 45 119
IBUPROFEN 51 41 47 72
ENALAPRIL MALEATE 50 36 48 22
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 19, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.